GW Pharmaceuticals

(ANTIMEDIA) Mainstream science is finally starting to accept what countless parents have known for years: cannabis treats childhood epilepsy.

On September 26, a marijuana-based childhood epilepsy drug took a step closer to winning approval when its maker announced promising phase 3 clinical trial results. [1]
Justin Gover, CEO of the British biotech company GW Pharmaceuticals, said that the children participating in the trial had previously tried 10 other anti-epileptic drugs. Despite using the medication, the young participants still experienced 3 seizures a day, approximately 90 a month. Said Gover:

A 120-patient trial showed patients taking cannabis-based Epidiolex were able to reduce their convulsive seizures by 39 percent.
The post New Cannabis Drug Able to Reduce Seizures by 39% for Some Epilepsy Patients appeared first on The Anti-Media.

GW Pharmaceuticals is expected to be given a green light for a cannabidiol drug (marijuana-based medicine) which has shown promise in the treatment of epileptic children, cutting epileptic attacks down by as much as 100% (45% average). When will the Feds admit cannabis is a medical miracle?